MaSTherCell Chief Executive Officer
Hugues has over 15 years of experience as a CEO and is a serial entrepreneur in the life sciences and biotechnology industries. Prior to MaSThercell, Hugues was CEO and co-founder of Artelis, where he created strong value and assets, later selling the company to ATMI LS in a multi-million dollar deal. Hugues was also CEO of Kitozyme, the world's leading manufacturer of vegetable chitosan, where he successfully implemented the GMP-compliant production facility. Through education and experience, Hugues has developed strong specialities in bio-ventures, fundraising and financial management.
He's also currently the CEO of Univercells, a biomanufacturing engineering company that aims to make biologics available and affordable for all by reinventing the way they are manufactured across the globe. In addition, Hugues is director for Orgenesis, a development stage cell therapy company on a mission to end diabetes, and director for Vivaldi BioSciences, which develops more effective flu vaccines.
Director of Orgenesis
Since 2008, Ms. Caplan has been CEO of Kamedis, a company focused on utilising plant extracts for dermatology purposes. From 2004 to 2007, Ms. Caplan was CEO of GammaCan, a company focused on the use of immunoglobulins for the treatment of cancer. During the previous five years, Ms. Caplan has been a director of the following companies: Opticul Ltd., a company involved with optic based bacteria classification; Inmotion Ltd., a company involved with self-propelled disposable colonoscopies; Nehora Photonics Ltd., a company involved with non-invasive blood monitoring; Ocure Ltd., a company involved with wound management; Eve Medical Ltd., a company involved with hormone therapy for menopause and PMS; and Biotech Investment Corp., a company involved with prostate cancer diagnostics. Ms. Caplan has a M.Sc. in biomedical engineering from Tel-Aviv University specialised in signal processing; management for engineers from Tel-Aviv University specialised in business development; and a B.Sc. in mechanical engineering from the Technion Institute of Technology specialised in software and CAD systems.
BiondVax Pharmaceuticals Ltd. Chief Operating Officer
Dr. Shimon Hassin, Ph.D., serves as Chief Operating Officer at BiondVax Pharmaceuticals Ltd. Dr. Hassin has over 10 years of experience in Biotechnology, with specific expertise in the development of biopharmaceuticals. Prior to joining the company, Dr. Hassin was co-founder and Chief Executive Officer of Kadimastem. Before joining BiondVax, Dr. Hassin worked at InSight Biopharmaceuticals, a leading Israeli biotechnology company active in the area of Biogenerics. In his capacity as Head of Process Development, he was responsible for the manufacturing of a variety of Biogenerics such as therapeutic antibodies, cytokines and hormones. Dr. Hassin holds a Ph.D. degree in Biotechnology from the University of Maryland Biotechnology Institute and was a post-doctoral associate at the University of Bergen Center of Marine Biotechnology.
i-Tech Incubator General Manager
Graduated in Business Engineering from the Solvay Brussels School of Economics and Management (ULB), Bouillez is the General Manager of the i-Tech Incubator. She has impressive experience supporting young innovative companies.
"Research centres from universities generate a large number of innovative projects in life sciences and engineering. Valuing these projects has led to the creation of a significant number of spin-offs. Their success is dependent on three conditions: a good project, a good management team and adequate financing. Our role is to optimise these components for the projects we support".
Deputy Head of the ULB Finance Department
Françoise Magerman graduated as a Business Engineer from Solvay in 1991. She is Deputy Head of the ULB Finance Department and is responsible for Accounting, Financial Management of Research and Patrimonial Services. Being the representative of the University in the Theodorus investment fund, Ms Magerman is also involved as a Board member in several spin-off companies and partner associations.